Are you or your loved ones suffering from glioma?

You may be eligible to participate in a glioma clinical trial.

Are you or your loved ones suffering from glioma? You may be eligible to participate in a glioma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

H3 K27M-mutant High-Grade Glioma
NCT03295396 | Phase 2 | Interventional
Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from glioma?

You may be eligible to participate in a glioma clinical trial.

Are you or your loved ones suffering from glioma? You may be eligible to participate in a glioma clinical trial.

Recruiting

Male & Female

18 +

years old

This study is looking to recruit 39 Participants

The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.

Available locations
Levine Cancer Institute

Levine Cancer Institute

Recruiting 1021 Morehead Medical Drive, Charlotte, NC, USA 28204

M D Anderson Cancer Center

M D Anderson Cancer Center

Recruiting 1515 Holcombe Boulevard, Houston, TX, USA 77030

New York University School of Medicine

New York University School of Medicine

Recruiting 550 1st Avenue, New York, NY, USA 10016

University of California San Francisco

University of California San Francisco

Recruiting 505 Parnassus Avenue, San Francisco, CA, USA 94143-0112

Interested in participating?
Oncoceutics Inc
Sponsored by Oncoceutics Inc

To get started, please choose a location